Buy Rating Affirmed for Precision BioSciences on Promising Gene Editing Prospects and Strong Financials

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Precision BioSciences (DTIL – Research Report). The associated price target was lowered to $60.00.

Patrick Trucchio has given his Buy rating due to a combination of factors surrounding Precision BioSciences’s promising gene editing programs and their financial positioning. Trucchio highlighted the company’s advancements in their lead gene editing therapeutic candidate, PBGENE-HBV, targeting hepatitis B virus, which is nearing its final stages before potential clinical trials. With a strategic focus on developing a best-in-class gene editing franchise, Precision BioSciences is also progressing with other in vivo gene editing candidates, including PBGENE-PMM for primary mitochondrial myopathy. The collaboration with industry giants Novartis and Eli Lilly, and the company’s solid financial runway—extended into the second half of 2026 due to various funding strategies—further bolster the optimism in the stock.

Additionally, the preclinical data for PBGENE-HBV suggests that it has the potential to transform the treatment landscape for chronic hepatitis B by achieving functional cure endpoints. Trucchio was impressed by the significant reduction of key viral replication indicators and the absence of detectable off-target edits, which indicates a strong safety profile. The promise of PBGENE-HBV as either a monotherapy or in combination with other treatments to cure chronic hepatitis B is seen as a game-changer in the field. These factors collectively contribute to the analyst’s positive outlook on Precision BioSciences’s stock, consolidating the Buy rating and setting a high price target even after adjusting for a reverse stock split.

In another report released yesterday, JonesTrading also maintained a Buy rating on the stock with a $30.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Precision BioSciences (DTIL) Company Description:

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company’s propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.